Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX8394 in Advanced Solid Tumors
NCT02012231Phase 1Terminated
- Sponsor
- Fore Biotherapeutics
- Start
- Feb 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of plixorafenib in melanoma, thyroid cancer, colorectal cancer (CRC) and 5 more (4 arms), sponsored by Fore Biotherapeutics. Primary endpoints: Recommended Phase 2 Dose at 1 year and Safety of PLX8394 at 1 year. Started Feb 2014; status: terminated.
02
Drugs
plixorafenib
03
Conditions
melanomathyroid cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02012231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012231.